Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558354 | 0.86 | ALDH1A1 (0.43) | ALDH1A1LTB4RLTB4R2MCOLN3GBA1 | |
| SCHEMBL7241734 | 0.85 | HTR6 (0.46) | BLMTSHRLTB4RLTB4R2 | |
| SCHEMBL31558350 | 0.84 | LTB4R (0.53) | BLMTSHRLTB4RLTB4R2GBA1 | |
| SCHEMBL7246265 | 0.84 | LTB4R (0.43) | BLMTSHRLTB4RLTB4R2 | |
| SCHEMBL7244243 | 0.83 | LTB4R (0.47) | ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL7243872 | 0.79 | GRIN2B (0.45) | LMNAALDH1A1 | |
| SCHEMBL7250161 | 0.78 | OPRD1 (0.43) | BLMTSHROPRM1OPRK1 | |
| SCHEMBL4170947 | 0.77 | HTR2A (0.47) | ALDH1A1 | |
| SCHEMBL7249487 | 0.76 | HTR6 (0.46) | BLMTSHRLMNAALDH1A1LTB4R | |
| SCHEMBL7244280 | 0.76 | HTR6 (0.46) | BLMTSHRLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | BLM 952/4885TSHR 3603/4885LMNA 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.